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Dynamic interplay between catalytic and lectin
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Protein O-glycosylation is controlled by polypeptide GalNAc-transferases (GalNAc-Ts) that
uniquely feature both a catalytic and lectin domain. The underlying molecular basis of how
the lectin domains of GalNAc-Ts contribute to glycopeptide specificity and catalysis remains
unclear. Here we present the first crystal structures of complexes of GalNAc-T2 with
glycopeptides that together with enhanced sampling molecular dynamics simulations
demonstrate a cooperative mechanism by which the lectin domain enables free acceptor sites
binding of glycopeptides into the catalytic domain. Atomic force microscopy and small-angle
X-ray scattering experiments further reveal a dynamic conformational landscape of
GalNAc-T2 and a prominent role of compact structures that are both required for efficient
catalysis. Our model indicates that the activity profile of GalNAc-T2 is dictated by
conformational heterogeneity and relies on a flexible linker located between the catalytic and
the lectin domains. Our results also shed light on how GalNAc-Ts generate dense decoration
of proteins with O-glycans.
DOI: 10.1038/ncomms7937 OPEN
1 BIFI, University of Zaragoza, BIFI-IQFR (CSIC) Joint Unit, Mariano Esquillor s/n, Campus Rio Ebro, Edificio IþD, Zaragoza 50018, Spain. 2 Departamento de
Quı´mica, Universidad de La Rioja, Centro de Investigacio´n en Sı´ntesis Quı´mica, E-26006 Logron˜o, Spain. 3 LMA, INA, Universidad de Zaragoza, 50018
Zaragoza, Spain. 4 Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, School of Dentistry, University of Copenhagen,
Copenhagen DK-2200, Denmark. 5 Departament de Quı´mica Orga`nica i IQTCUB, Universitat de Barcelona, Martı´ i Franque`s 1, 08028 Barcelona, Spain.
6 Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK. 7 Instituto de Medicina Molecular, Faculdade de Medicina,
Universidade de Lisboa, Av Prof Egas Moniz, 1649-028 Lisboa, Portugal. 8 ICREA, Passeig Lluı´s Companys 23, 08020 Barcelona, Spain. 9 Centre de Biochimie
Structurale, INSERM U1054, CNRS UMR 5048, Universite´ Montpellier 1 and 2, 29 rue de Navacelles, 34090 Montpellier, France. 10 Departamento de Fı´sica
Teo´rica, Universidad de Zaragoza, Zaragoza 50009, Spain. 11 Fundacio´n ARAID, 50018 Zaragoza, Spain. wPresent address: Department of Chemistry,
Britannia House, 7 Trinity Street, King’s College London, London SE1 1DB, UK. Correspondence and requests for materials should be addressed to R.H.-G.
(email: rhurtado@bifi.es).
NATURE COMMUNICATIONS | 6:6937 |DOI: 10.1038/ncomms7937 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
M
ucin-type (GalNAc-type) O-glycosylation is by far the
most differentially and complex regulated type of
protein glycosylation, and likely the most abundant
with over 80% of all proteins passing through the secretory
pathway that is predicted to be O-glycosylated1. In metazoans,
this post-translational modification is initiated by a large
family (20 in humans) of polypeptide N-acetylgalactosaminyl-
transferases (GalNAc-Ts), which transfer a GalNAc residue from
uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) to
Ser/Thr side chains in the presence of manganese2. These
isoenzymes are grouped in CAZy database as family 27 (ref. 3)
and further classified into several subfamilies based on the
enzyme protein sequences and the genomic structures of the
encoding genes2. They are also classified into two major classes
based on their primary acceptor substrate preferences for peptides
and partially glycosylated GalNAc-glycopeptides. The acceptor
substrate specificities of these isoenzymes are distinct but partly
overlapping, and so far no clear global consensus motifs or
isoform-specific motifs that govern protein O-glycosylation have
emerged, although improved algorithms for predictions have
been proposed1,4. These isoenzymes have different cell and tissue
expression patterns2 and they play important roles in health and
disease5,6. The immediate product of the GalNAc-Ts is also
known as the Tn (GalNAca1-O-Ser/Thr) antigen (if sialylated the
STn (NeuAca2-3GalNAca1-O-Ser/Thr) antigen), and while this
structure in normal cells is masked by elongation of the glycan
structures by a number of other glycosyltransferases, expression
of Tn (and STn) is a hallmark of cancer cells7,8. Expression of
these immature truncated O-glycans is strongly correlated with
poor prognosis and low overall survival and truncated O-glycans
serve as targets for immunotherapies9. Mechanisms leading to
expression of Tn and STn O-glycans in cancers include somatic
mutations and/or epigenetic silencing of the private chaperone
Cosmc responsible for O-glycan elongation10 as well as relocation
of GalNAc-Ts from Golgi to endoplasmic reticulum11. More
recently, we have shown that the truncated O-glycophenotype
appear to directly induce oncogenic features with enhanced
growth and invasion12.
GalNAc-T isoforms contain an N-terminal catalytic domain
adopting a GT-A fold and a unique C-terminal lectin domain,
classified as a carbohydrate-binding module (CBM) 13 in the
CAZy database3, with a b-trefoil fold that are connected through
a short flexible linker13–16. A key structural feature of these
enzymes in catalysis is the existence of a flexible loop formed by
residues Arg362 to Ser373 (residue numbers in GalNcAc-T2) that
adopts different conformations during the catalytic cycle and
renders the enzyme catalytically inactive or active16.
Another level of complexity in this family of enzymes comes
from the lectin domains that play a very important role in the
O-glycosylation process by modulating the specificity and the use
of partially glycosylated GalNAc-glycopeptide substrates17,18.
Lectin domains or CBMs also exist in some glycosyl hydrolases
(GHs). For these enzymes, CBMs are important for targeting the
catalytic GHs onto their substrates and enhancing their hydrolytic
activity, and even can potentiate the action of a cognate catalytic
module towards polysaccharides in intact cell walls through
the recognition of nonsubstrate polysaccharides19,20. We have
hypothesized that the lectin domains of GalNAc-Ts are required
to accommodate efficient glycosylation of diverse protein
sequences with densely located acceptor sites in a process
where the lectin domains bind to initially attached GalNAc
residues and promote catalytic efficiency and further
incorporation to less efficient acceptor sites2,21. The importance
of the lectin domains is exemplified by the rare disease familial
tumoral calcinosis associated with hyperphosphatemia, which is
caused by deficiency in GalNAc-T3 or FGF23 (ref. 22). Thus, loss
of GalNAc-T3, which mediates the O-glycosylation of Thr178 in
a proprotein convertase-processing site (RHTR179k) of FGF23,
results in inactivation of FGF23 and cause hyperphosphatemia22.
Notably, glycosylation of Thr178 in FGF23 by GalNAc-T3
requires the lectin domain and a GalNAc O-glycan positioned
N-terminal to this site5. However, the mechanism for how these
unique lectins modulate O-glycosylation is essentially unknown.
In this regard, recent studies have provided evidence that the
N/C-terminal orientation of GalNAc residues and available
proximal acceptor sites is an important factor in the overall
catalytic activity and specificity of GalNAc-Ts, and moreover, that
the preferences for this orientation differs between isoforms23.
This adds another level of differential regulation and complexity
to the O-glycosylation process and help to explain how large
mucins with thousands of glycosites are densely decorated with
O-glycans with high fidelity. Interestingly, studies with random
glycopeptide libraries suggest that there is a distance preference
for the effect of prior GalNAc residues, in which the optimal
distance from the prior site of glycosylation corresponds to
residues that are located approximately ten residues apart for
GalNAc-T1, T2 and T13, and eight or nine residues for T3
(ref. 23). This distance preference suggests a cooperative binding
of GalNAc-Ts to GalNAc-glycopeptide substrates through both
the catalytic and lectin domains23.
Here we present the first crystal structures of the inactivated
and activated forms of the GalNAc-T2 isoform in binary and
ternary complexes with different GalNAc-glycopeptides enabling
us to study in detail the lectin-mediated modulatory mechanism
of catalysis. The crystal structures, in combination with
metadynamics simulations, provides a rational explanation of
why this isoform favours glycosylation of acceptor sites
positioned at the N-terminal region and ten residues apart from
the prior GalNAc moieties. We also present single-molecule
atomic force microscopy (AFM) and small-angle X-ray scattering
(SAXS) data indicating that GalNAc-Ts sample a highly complex
conformational landscape formed by ensembles of compact and
extended structures. Analysis of SAXS shows that alterations of
the equilibrium towards the compact structures in the presence of
acceptor substrates appear to be required for lectin-mediated
catalysis. In addition, by using a coarse-grained model, we
demonstrate that GalNAc-T2 structural heterogeneity, as well as
its activity profile, can be simply related to the mechanical
properties of the flexible linker.
Results
Architecture of the GalNAc-glycopeptides complexes. To
understand how lectin domains direct O-glycosylation, we
obtained tetragonal crystals of GalNAc-T2 in complex with three
GalNAc-glycopeptides (Table 1 and Supplementary Table 1). The
resulting crystals allowed us to solve the structure at high reso-
lution (from 1.48 to 1.67 Å) and easily interpret the density maps
(Table 1). Despite the co-crystallization experiments were
performed with GalNAc-T2, UDP and Mnþ 2, we obtained bin-
ary complexes with glycopeptides MUC5AC-Cys13 and
MUC5AC-3-13 (the binary complexes are referred to the enzyme
complexed to the different glycopeptides MUC5AC-Cys13 and
MUC5AC-3-13, respectively), and a ternary complex with
MUC5AC-13 (the ternary complex is referred to the enzyme
bound to UDP and the glycopeptide MUC5AC-13; Fig. 1a,b).
Within the asymmetric unit (AU) of I41 crystals, one molecule
of GalNAc-T2 is arranged as a dimer with another molecule from
the neighbouring AU (Fig. 1a). These compact dimeric forms are
consistent with previous structures of GalNAc-T2 in complexes
with UDP and Mnþ 2 (protein data bank (PDB) entry 2FFV14),
and UDP or UDP-GalNAc/Mnþ 2 and peptides (PDB entries
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4D0T, 4D0Z and 4D11 (ref. 16)). However, members of this
family of enzymes are proposed to be monomers in
solution16,24,25 (discussed below). The crystal structures show
that the typical GT-A fold is located in the N-terminal region and
the lectin domain is located in the C-terminal region (Fig. 1a).
The density for all the glycopeptides and UDP/Mnþ 2 was well
defined in most monomers (Fig. 1b). These results are further
supported by tryptophan fluorescence spectroscopy experiments
showing that peptides/glycopeptides can bind fairly well to
GalNAc-T2 in the absence or presence of UDP/Mnþ 2
(Supplementary Table 2). The dissociation constants (Kds) of
the peptides were in the low mM range and very similar among
them except for the naked peptide MUC5AC, in which the Kd in
the absence of UDP/Mnþ 2 is fourfold better than in the presence
of the nucleotide (Supplementary Table 2).
The structures also feature a flexible loop that can oscillate
between closed and open conformations (Fig. 1c,d) and is
associated with the active and inactive states of the enzyme, as
described in previous studies14,16. We also reported that the
UDP-GalNAc moiety was a key factor to maintain the flexible
loop in a closed conformation regardless of whether the peptide
was present or not (Fig. 1c and PDB entry 4D0T)16. On the
contrary, previous structures containing UDP (Fig. 1c and PDB
entries 2FFU14, 4D11 (ref. 16) and 2FFV14) including our
complex of GalNAc-T2-UDP-MUC5AC-13 (Fig. 1c,d) exhibit a
mix of loop conformations (semi-open, open and closed)
along the catalytic cycle (Fig. 1c)16. Furthermore, the flexible
loop dynamics are coupled to the key catalytic residue Trp331
mobility that can adopt ‘in’ (inside of the active site) and ‘out’
(outside of the active site) conformations, which in turn are
associated to the active or inactive states of GalNAc-T2,
respectively (Fig. 1d). Interestingly, MUC5AC-13 was bound to
an active form of GalNAc-T2, whereas MUC5AC-Cys13 and
MUC5AC-3-13 were unpredictably trapped bound to the inactive
form of GalNAc-T2 (Fig. 1b–d). In these cases, the flexible loop
was found in an open conformation, different from the one
previously described for the GalNAc-T2-UDP complex (PDB
entry 2FFV14 and root-mean-square deviation (RMSD) of 4.68Å
for aligned Ca atoms corresponding to the flexible loop;
Fig. 1c,d), which further demonstrates the loop versatility.
Peptide and lectin domain-binding sites. As shown in the
crystal structures (Fig. 1), the GalNAc-T2-binding site is large
and set up by three regions: the sugar nucleotide, the
peptide and the lectin domain-binding sites (Fig. 2a). In the
GalNAc-T2-MUC5AC-13-UDP complex, GalNAc-T2 is in an
active state with the flexible loop in a closed conformation
with UDP in the sugar nucleotide-binding site, and MUC5AC-13
acts as a bridge between the catalytic unit and the lectin
Table 1 | Data collection and refinement statistics*.
GalNAc-T2 -MUC5AC-Cys13 GalNAc-T2-MUC5AC-3,13 GalNAc-T2-MUC5AC-13-UDP-Mnþ 2
Data collection
Space group I 41 I 41 I 41
Cell dimensions
a, b, c (Å) 87.35, 87.35, 178.43 87.2, 87.2, 179.07 87.27, 87.27, 178.59
a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (Å) 20–1.67 (1.76–1.67) 20–1.48 (1.56–1.48) 20–1.65 (1.74–1.65)
Rmerge
w 0.103 (0.653) 0.058 (0.535) 0.043 (0.601)
I/s(I) 11.3 (3.0) 18.6 (2.3) 22.1 (2.9)
Completeness (%) 99.8 (100) 99.6 (97.5) 99.8 (99.2)
Multiplicity 8.9 (9.2) 8.6 (4.2) 6.7 (5.8)
Refinement
Resolution (Å) 20–1.67 (1.76–1.67) 20–1.48 (1.56–1.48) 20–1.65 (1.74–1.65)
No. of reflections (test) 76,947 (2,308) 110,205 (3,306) 79,709 (2,391)
Rwork/Rfree
z 0.196/0.232 0.149/0.178 0.156/0.185
No. of atoms
Protein 4,023 4,040 3,991
Glycopeptide 114 129 107
Sulfate 60 155 110
Ethylenglycol 56 — —
UDP — — 25
Mnþ 2 — — 1
Water 556 800 614
B-factors (Å2)
Protein 22.41 19.03 26.71
Glycopeptide 33.81 19.46 19.29
Sulfate 56.01 61.48 69.44
Ethylenglycol 38.75 — —
UDP — — 21.88
Mnþ 2 — — 19.29
Water 33.51 35.06 39.02
R.m.s deviations
Bond lengths (Å) 0.019 0.012 0.013
Bond angles () 2.027 1.613 1.627
PDB ID 5ajn 5ajo 5ajp
UDP, uridine diphosphate.
*Highest resolution shell is shown in parenthesis.
wRmerge¼ShklSi |I(hkl)i—[I(hkl)]|/Shkl Si I(hkl).
zRwork¼Shkl|F(hkl)o—[F(hkl)c]|/Shkl F(hkl)o; Rfree was calculated as Rwork, where F(hkl)o values were taken from 3% of data not included in the refinement.
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domain (Fig. 2a). MUC5AC-13 as well as MUC5AC-Cys13
and MUC5AC-3-13 glycopeptides have a C-terminal GalNAc
moiety that establishes interactions with the lectin domain-
binding site (Figs 1 and 2a). The sugar moiety for the three
above glycopeptides adopts a perpendicular conformation
with respect to the peptide backbone. This also supports
previous data suggesting that Cys residues bound to a
GalNAc moiety mimic fairly well Thr residues linked to the same
sugar26.
It is noteworthy that the C-terminal of MUC5AC-13,
compared with the naked EA2 peptide, follows a divergent
pathway towards its C-terminus (Fig. 2a,b). Both, MUC5AC-13
and EA2, bind in a competitive manner engaging potential
acceptor sites close to the UDP (Fig. 2a,b). The different binding
modes found for the peptides emphasize the plastic nature of the
peptide-binding groove, which makes it potentially important to
sample a large number of different acceptor substrates with
multiple acceptor sites.
At the peptide-binding groove level, the specificity of
GalNAc-T2 for the peptides MUC5AC-13 and EA2 (same
interactions are also present for MUC5AC-Cys13 and
MUC5AC-3-13) is governed mainly by hydrophobic interactions
with Val255, Phe361, His365, Leu270, Phe377, Phe280, Trp282
and Tyr284 that are residues located in a solvent-exposed
hydrophobic pocket (Fig. 2a,b). Both peptides are also tethered
by hydrogen bonds with Trp282, His365 and Ser373 (Fig. 2a,b).
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Figure 1 | Crystal structures of GalNAc-T2 in complex with glycopeptides. (a) Cartoon representation of the overall dimeric structure of GalNAc-T2 in
complex with UDP-MUC5AC-13. The monomers are coloured in grey and blue-white, respectively. UDP, MUC5AC-13 and flexible loop in yellow are
indicated by arrows. The nucleotide and the glycopeptide are depicted as orange and green carbon atoms, respectively. The GalNAc moiety covalently
bound to Thr13 is depicted as orange carbon atoms. (b) Electron density maps are FO–FC syntheses (blue) contoured at 2.0s for the ligands. The residues
(Asp224, His226 and His359) coordinated to the manganese atom (shown as a pink sphere) are illustrated as black carbon atoms. Colours for the ligands
are the same as above. (c) Surface representation of binary and ternary GalNAc-T2 complexes showing different active and inactive states. Protein, flexible
loop, nucleotides, GalNAc moiety and peptides are coloured in grey, yellow, brown, orange and green, respectively. The active and inactive states are
indicated as closed and open conformations, respectively. (d) Close-up view of GalNAc-T2-MUC5AC-Cys13, GalNAc-T2-MUC5AC-13-UDP and GalNAc-
T2-UDP (PDB entry 2FFV14) complexes. The colours are the same as shown above. The loop in which Trp331 is located is in black. In the latter complex,
UDP is shown as inverted relative to the most frequent position found for UDP and has been proposed to be a conformation ready to depart from the active
site14,16. Trp331 is depicted as black carbon atoms and adopts ‘in’ and ‘out’ conformations.
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Of four amino acids widely conserved among isoforms (Phe361,
Phe280, Trp282 and Tyr396; Supplementary Fig. 1a), Phe361,
Phe280 and Trp282 are key residues in the recognition of
common peptide motifs such as Pro-x-Pro (where x is usually a
small hydrophobic residue; Fig. 2a,b) found in acceptor
substrates. In fact, site-directed mutagenesis of Phe361 and
Trp282 to Ala residues almost eliminates the activity of the
enzyme, and thus confirms the importance of these amino acids
in peptide recognition (Fig. 2c and Supplementary Fig. 1b).
In all cases, the lectin domains appear to interact only with the
GalNAc moiety of the glycopeptides without any discernable
interaction with the peptide backbone (Fig. 2a). The lectin
domains of GalNAc-Ts consist of three pseudo repeat regions
termed a, b and g, which each potentially may bind GalNAc
(Supplementary Fig. 1c). However, it is accepted that the lectin
domains from human GalNAc-T1 contain two functional
GalNAc-binding sites (a and b), whereas GalNAc-T2 (a),
GalNAc-T4 (a) and GalNAc-T10 (b) contain only one21.
Unlike GalNAc-T10, in which the sugar moiety is located on
the b-site15, the C-terminal GalNAc of the glycopeptides in
GalNAc-T2 is located on the a-site of the lectin domain
and is tethered by conserved residues such as Asp458, Asn479,
Tyr471 and His474 (equivalent residues for b-binding site in
GalNAc-T10 are Asp525, Asn544, Tyr536 and His539; Fig. 2a
and Supplementary Fig. 1a). This explains why Asp458 (the only
amino acid establishing two hydrogen bonds with the sugar
moiety, Fig. 2a) is important for GalNAc-peptide substrate
specificity and consequently in tuning the glycosylation profile of
these enzymes11,17,27.
The sugar nucleotide-binding site. Both the UDP and
glycopeptides can bind to a versatile sugar nucleotide-binding site
with a flexible loop adopting both open and closed conformations
(Figs 1 and 3a). Although the N-terminal of MUC5AC-13 is
covered by the flexible loop, the N-termini of MUC5AC-Cys13
and MUC5AC-3-13 are exposed to the solvent and inserted
into the sugar nucleotide-binding site (Fig. 1c). The latter two
glycopeptides adopt very similar binding modes, although some
differences stand out towards the N-terminus (RMSD of
0.72 Å for aligned Ca atoms corresponding to residues Gly1-
Ser5). The Gly1–Ser5 interactions with GalNAc-T2 are mainly
governed by common hydrogen bonds with Glu334, Arg362 and
Lys363, and distinct ones in particular for Asp224 and Tyr367
(Fig. 3a). There is an extra sulfate molecule in the GalNAc-T2-
MUC5AC-Cys13 complex that occupies the same position
found for the manganese atom in the competent structures
such as the GalNAc-T2-MUC5AC-13-UDP complex (Fig. 3a;
the interactions of GalNAc-T2 with UDP were discussed
earlier)14,16. MUC5AC-Cys13 establishes further hydrogen bond
interactions with this sulfate molecule (Fig. 3a). For the
diglycosylated peptide, an unprecedented GalNAc-binding site,
formed by aromatic residues such as Phe280, Tyr367 and
Phe377, is found (Fig. 3a). This GalNAc moiety linked to Thr3
is tethered by Ser5, Phe280, Ala307, Gly333 and Phe377,
and is found close to the sugar unit of UDP-GalNAc (average
atomic shift of 5.29Å; see Fig. 3a,b for further information).
It is also important to emphasize that the lectin domain,
through the interaction with the C-terminal GalNAc moiety of
MUC5AC-13, imposes N-terminal residues of the glycopeptide
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close to UDP (Fig. 3a). Particularly, Ser5 is quite close to UDP
(the distance between the Ser5 oxygen and the b-phosphate is
3.81Å) and is potentially in a position to attack the anomeric
carbon of UDP-GalNAc (see Fig. 3c for further information).
This structure is compatible with the fact that GalNAc-T2 prefers
to glycosylate N-terminal acceptor sites of glycopeptides
efficiently, but the structure itself does not explain why Thr3 is
the most favourable acceptor site, as shown earlier by kinetic
studies, or why glycosylation optimally takes place at acceptor
sites located ten residues N-terminal of an existing site of
glycosylation17,23.
Structure-guided metadynamics. In an attempt to answer why
Thr3, positioned ten residues N-terminal to the prior glycosylated
Thr13, is the most favourable acceptor site in comparison to less
efficient acceptor sites such as Ser5 and Thr9, we modelled the
binding of a glycopeptide to GalNAc-T2 using an enhanced
sampling molecular dynamics (MD) approach (metadynamics)28.
A ternary complex of GalNAc-T2 with UDP-GalNAc and a
glycopeptide was used as the initial structure for the calculations.
Room temperature MD simulations were performed to
equilibrate the enzyme complex (see details in Supplementary
Methods). Afterwards, the binding of the glycopeptide to the
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active site was monitored by metadynamics using two collective
variables. The first variable was the distance between the centre of
mass of the UDP-GalNAc and the centre of mass of the side chain
of the peptide acceptor sites (Thr3, Ser5 or Thr9). This variable
measures directly the penetration of the peptide into the active
site. The second collective variable was taken as the RMSD of the
peptide structure and measures changes in peptide conformation.
The free energy landscapes of peptide binding reconstructed
from the metadynamics simulations show two main energy
minima for Thr3 (minima 1 and 2 in Fig. 3d) at distances of 20–
25Å (outer minimum) and 4.5 Å (inner minimum), respectively,
but only a broad outer minimum for Ser5 and Thr9 (3 and 4,
respectively, in Fig. 3d). The outer minima (1, 3 and 4)
correspond to conformations in which the peptide is far from
the active site and mainly interacts with the lectin domain
(Supplementary Fig. 2a). Instead, the inner minimum (2, Thr3
glycosylation) corresponds to a reactive conformation, very close
to the one found in the crystal structure of the GalNAc-T2-UDP-
MUC5AC-13 complex (Supplementary Fig. 2a). Similar inner
structures on the Ser5 and Thr9 maps are less stable than their
corresponding outer global minimum, and thus much less
populated. Consequently, the glycosylation reaction is expected
to be less efficient for Ser5 and Thr9 than for Thr3.
The order of the preferred glycosylation site can be easily
visualized by representing the free energy of the binding process
versus the distance between the acceptor amino acid and the
UDP-GalNAc donor (Supplementary Fig. 2b). It is important to
note that only Thr3 glycosylation shows a deep inner minimum
corresponding to reactive configurations.
A comparison of the protein structure for Thr9 and Thr3
glycosylation at short distances (Fig. 3e) shows that Thr9
glycosylation requires a highly compact and strained protein
conformation in which the lectin domain approaches the catalytic
domain. This conformation differs from the less compacted
structure found in our crystal structure in complex with UDP-
MUC5AC-13 (RMSD of 2.51Å for 495 aligned Ca atoms).
Notably, our simulation results are consistent with the previously
reported solution studies, in which Thr3 was shown to be
glycosylated preferentially over Ser5 and Thr9 (ref. 17), and also
explains why GalNAc-T2 prefers to glycosylate N-terminal
residues that are ten residues apart of a prior C-terminal
glycosite. However, several questions arise on the molecular
basis of how GalNAc-T2 achieves catalysis on residues close or
very distant to an already attached GalNAc O-glycan, or whether
the more compact structure shown above really exists in solution.
GalNAc-T2 adopts compact and extended conformations. To
understand the conformational state of GalNAc-T2 under ligand-
binding and -unbinding conditions, we applied initially time-
lapse AFM experiments. A series of AFM topography images
were recorded of single GalNAc-T2 molecules under different
conditions and in three distinguishable conformational states:
(i) a highly compact structure similar to the one above found
through molecular modelling (Figs 3e and 4a, top-left panel) and
in which the two domains interact closely even though a slot is
still observed between them; (ii) a compact structure similar to
our crystal structures that displays a clear slot (Fig. 4a, top-right
panel and Supplementary Fig. 3a) and (iii) extended structures
exhibiting fully separated domains (Fig. 4a, bottom panel and
Supplementary Fig. 3b). Our AFM experiments (Fig. 4a, bottom
panel and Supplementary Fig. 3b) support, for the first time,
that the extended state visualized in the crystal structure of
GalNAc-T2 in complex with UDP and the EA2 peptide (PDB
entry 2FFU14; Fig. 1c), in which the domains are separate, is not
an artefact of the crystallographic conditions.
The highly compact and compact species show height values of
E8–10 nm (Fig. 4a, top panel), whereas the average height for the
extended species is smaller, reaching E5 nm (Fig. 4a, bottom
panel). The size of the separated domains in the images is barely
larger than that estimated from the crystal structure (3.5 and
4.7 nm for the lectin and the catalytic domains, respectively, in
PDB entry 2FFU14) mainly as a result of hydration29. The
intermediate sizes observed for the compact species thus suggest a
slight overlap between both domains of the enzyme.
The enzyme in the apo form or bound to UDP or UDP-
GalNAc in the presence of Mnþ 2 adopts either the very compact
or the compact structure (Fig. 4a, top panel). However, the three
different conformational states are present when the enzyme is
either bound to EA2 or to glycopeptides such as MUC5ACs-Cys9
(see sequence in Supplementary Table 1) or MUC5AC-13 alone
or in combination with UDP/Mnþ 2 (Fig. 4a). Although our data
does not provide relevant information of the distribution between
different conformational states, clearly demonstrates the highly
dynamic nature of the GalNAc-T2 enzyme.
GalNAc-T2 monomeric compact conformations. To quantify
the GalNAc-T2 conformational states in solution, we measured
SAXS data for a large number of conditions. The capacity to
describe this data with available crystallographic structures for the
monomeric and dimeric forms of GalNAc-T2 was tested with the
programme CRYSOL30. The poor agreement of either structures
to the experimental SAXS curves (see Supplementary Table 3),
prompted us to study the enzyme flexibility using the Ensemble
Optimization Method (EOM)31. Ensemble analysis of solution
scattering curves for the apo enzyme at different concentrations
revealed a unique distinguishable bimodal distribution of
monomeric compact and extended structural ensembles that
have not been found before in other types of proteins by using
this method (Fig. 4b and Supplementary Figs 3c, 4 and 5). In
addition, the ensemble analysis identified compact dimers that
reached up to E40% at the highest concentration measured
(10mgml 1; Supplementary Table 3). Analysis of the data shows
that both monomeric conformation ensembles are similarly
populated but do not display a continuum of conformational
states. The radius of gyration (Rg) ranges between RgE24–29.5
and E31–36Å for the compact and extended structures,
respectively, with negligible population in between (Fig. 4b). As
already mentioned, a small percentage of potential structures with
Rg between E29.5 and 31Å are not displayed because they are
likely insufficiently stable to be detected (Fig. 4b). These data
reinforce the GalNAc-T2 dynamics inferred from our AFM
experiments and demonstrates that GalNAc-T2 is even more
flexible than shown by AFM experiments. In contrast to AFM,
SAXS is also able to identify a significant population of dimers
that supports the dimeric arrangement found for our crystal
structures, with the exception of the PDB entry 2FFU14, in which
the enzyme is monomeric (we used the PISA server to determine
the quaternary structure of GalNAc-T2 in the crystals). The SAXS
fits with EOM were notably better when the three crystallographic
dimeric arrangements were combined with the monomeric forms
(Fig. 4b, Supplementary Figs 3c, 4 and 5, and Supplementary
Methods). In particular, three different pools were built consisting
in 10,000 monomeric conformations that were separately
enriched with 100 copies of the theoretical curves of each of
the three dimeric arrangements tested (see Supplementary
Methods). The best fit was achieved when the most compact
dimer that possesses a buried area of 1,689Å2 (PDB entry
2FFV14) was used. Dimers visualized in crystal structures with a
tetragonal space group appear to be the most flexible compact
structures of all dimers with E750Å2 of buried area. This latter
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arrangement may explain why this particular dimer can bind
glycopeptides. In all three cases, the dimers display similar
contacts between the lectin domains and the lectin of one
monomer with the catalytic domain of a second monomer
(Fig. 4b and Supplementary Fig. 3c).
Notably, the GalNAc-T2-UDP-MUC5AC-13 complex with an
Rg of 26.41Å is one of the most populated compact molecules in
solution unlike less representative structures such as the one
found for the PDB entry 2FFU14 with Rg of 30.5 Å (Fig. 4b). This
result exemplifies that GalNAc-T2 preferentially adopts
conformations that might be important for catalytic aspects of
this enzyme.
Further SAXS experiments were carried out in the presence
of the ligands, which provided very intriguing results
(Supplementary Table 3). The enzyme either without ligands or
complexed with UDP or UDP-GalNAc shows a higher percentage
of dimers (28–44%) relative to the enzyme in complex with
glycopeptides, naked peptides or peptides-UDP (0–28%;
Supplementary Table 3). In particular, dimers almost disappear
from solution when GalNAc-T2 at a fixed concentration of
5mgml 1 is incubated with increasing concentrations of
Muc5AC-13 (Supplementary Table 3 and Supplementary
Figs 3d and 5). Moreover, similar amounts of compact
and extended monomeric ensembles exist for the enzyme
without ligands or complexed with UDP or UDP-GalNAc;
although in some cases, a slight increase in the amount of
extended conformations occurs (Supplementary Table 3).
This equilibrium is partly shifted to compact monomeric forms
in the presence of naked peptides and significantly shifted
in the presence of glycopeptides alone or with UDP (reaching
values of 59–70% in the presence of peptides; Fig. 4c and
Supplementary Table 3). Overall, these results indicate a
direct association between the distribution of GalNAc-T2
conformation states and acceptor substrate binding with
catalysis, and consequently, the glycosylation profile of
GalNAc-T2 (Fig. 4d). In particular, an increase of the monomeric
compact structures ensemble appear to be required for catalysis
on glycopeptides.
The role of the flexible linker. To further understand the unique
dynamics of GalNAc-T2 and the consequences for catalysis, we
developed a simple computational model in which the protein is
treated as two interacting rigid domains, connected by a flexible
linker that is described as a worm-like-chain (WLC model is used
to describe the behaviour of semi-flexible polymers; Fig. 5a)32.
The model predicts, at a qualitative level, the bimodal nature of
the Rg distribution revealed by SAXS data (Fig. 5b).
9,96 8,36
0,00
0,00
5,36
22
Glycopeptide
Glycopeptide
(SAXS)Po
pu
la
tio
n
Po
pu
la
tio
n
(SAXS)
UDP
(2FFV)
(2FFU)
(2FFV)
UDP-MUC5AC-13
24 26 28 30 32 34 36 38
Rg (Å)
22 24 26 28 30 32 34 36 38
Rg (Å)
0,00
5,16
0,00
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Within this model, the peak at high values of the Rg (Rg¼ 31–
37Å) is associated with the equilibrium distribution of the WLC,
whereas the peak at low values of the Rg (Rg¼ 24.5–29.5Å)
corresponds to the interaction of both domains (Fig. 5b and
Supplementary Fig. 6). In this context, the addition of peptides is
expected to increase the effective interdomain interaction by
increasing the interaction surface. Accordingly, if we strengthen
the interaction energy (e; see Supplementary Methods), we can
reproduce the increase of the peak at lower Rg (Fig. 5b).
Importantly, this simple model can shed light on the different
catalytic activity of GalNAc-T2 on glycopeptide substrates in
which multiple acceptor sites are found at different distances
from a GalNAc O-glycan at a fixed position (Fig. 5c). The crystal
structure of the GalNAc-T2-UDP-MUC5AC-13 complex sug-
gests that the GalNAc moiety of a glycopeptide substrate may first
bind to the lectin domain, which leads to enhance the probability
that GalNAc-T2 transfers another GalNAc residue to an acceptor
site approximately ten residues N-terminal of the first GalNAc
residue located at the lectin domain-binding site. This rationale
may help to explain previous work, in which the catalytic
efficiency of GalNAc-T2 is higher with glycopeptides than with
naked peptides that only contain one acceptor site23.
Despite the fact that the catalytic process is intrinsically not
one at equilibrium, the equilibrium behaviour of our simple
model grasps the fundamental aspects of the enzymatic activity.
By keeping the first glycosylated site bound to the lectin domain
at point P2 (Fig. 5a), only the probability that the acceptor site of
the peptide (also described as a WLC) is found in the correct
position P1 at the active site is taken into account (see Methods
and Supplementary Methods). Our computational model reason-
ably reproduces not only the previously reported broad
glycosylation profile of GalNAc-T2, but also the peak where a
maximum in the enzymatic activity is achieved, which in turn
corresponds to an acceptor site ten residues apart from a prior
site of glycosylation23 (Fig. 5c).
The flexible linker is a unique feature of the GalNAc-T
isoenzymes whose motion is responsible for the GalNAc-T2
dynamics, and consequently, the glycopeptide glycosylation
capacity of GalNAc-T2. The flexible linker is such an important
structural feature that if we computationally fix it in its position
in the crystal structure, the glycosylation activity profile changes
and the predicted activity decreases significantly (E5,000-fold
reduction; Supplementary Fig. 7).
In summary, the glycosylation activity profile of GalNAc-T2 is
directly coupled to the flexible linker motion that dictates the
unique dynamics of GalNAc-T2, and to the GalNAc-T2 binding
to glycopeptides that increases the population of compact
structures. This model, which is independent of whether the
glycopeptides have prior GalNAc O-glycans N- or C-terminal to
available to acceptor sites, might help to explain the glycosylation
profile of other GalNAc-Ts isoforms.
Discussion
In the present study, we have determined the first crystal
structures of GalNAc-T2 in complex with defined GalNAc-
glycopeptide substrates. These structures in combination with
AFM and SAXS experiments, as well as with theoretical
simulations, reveal how GalNAc-T2 selectively glycosylates
unused acceptor sites located in the N-terminal and optimally
ten residues apart from a prior GalNAc glycan. Our results show
that GalNAc-T2 populates an ensemble of compact and extended
monomeric structures, as well as dimeric ones. In the presence of
the acceptor substrates, the dimers disappear while the compact
monomeric structures get more populated than the extended one,
thus pointing at a prominent role of compact structures for
enzymatic activity. Although flexibility in an enzyme is hardly
surprising, the picture emerging from our results suggests a
peculiar role of the flexible linker, which acts as a conformational
dial to foster glycosylation of substrate peptides with different
22
C2
B
P2
P2
P1
P1
C1
A
r

G
2 4 6 8 10 12 14 16 18 20
Distance (residues)
Po
pu
la
tio
n
24 26 28 30 32 34 36 38
Rg (Å)
0.15
0.10
0.05
0.00Ac
tiv
ity
 (a
rbi
tra
ry 
un
its
)
Figure 5 | Coarse-grained theoretical model of GalNAc-T2. (a) The crystal structure of GalNAc-T2-UDP-MUC5AC-13 (bottom left) is taken as a
reference for the model (bottom, right). The apo form, without the peptide (green), is obtained by removing the latter from the coordinates file. Upon fixing
the relative orientation of the two domains (red and yellow for the lectin and catalytic domains, respectively), protein conformations depend on the flexible
linker (grey), modelled as a (non-extendable) semi-flexible chain with an attractive interaction between its ends. All other conformations of the protein (top
left) are modelled on the basis of the previous one, by letting the end-to-end vector (r) explore the region within a cone (light grey) of angular amplitude
2y0 (see Supplementary Methods for details). In the holo-form, the peptide (green) is modelled as a WLC of length (l) residues (the distance between the
glycosylating sites on the ligand), bound at P2 on the lectin domain. The enzymatic reaction can take place in any protein conformation providing that the
ligand free-end finds correct place P1 on the catalytic domain. (b) Model predictions for the probability distribution [G(Rg)] of the radius of gyration Rg. The
apo-form is shown as a blue solid line, whereas the holo-form complexed with peptide is shown as a red dashed line. (c) Enzymatic activity [s(l,lc)] as a
function of the residue separation (l) between potential glycosites and a prior fixed glycosite of the glycopeptides (see Supplementary Methods).
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distances between sites of sequential glycosylation. We demon-
strate that the lectin domain, which is a unique feature of the
large GalNAc-T isoenzyme family, modulates the catalytic
functions and coordinates the follow-up order of glycosylation
of protein substrates.
In contrast to the role of the GHs CBMs, GalNAc-Ts lectin
domains are not only important to bind to the sugar moiety of
glycopeptides, but also to guide catalysis to other unused acceptor
sites. This study provides further support for the general model
that we proposed for GalNAc-O-glycosylation, where a number
of GalNAc-T isoenzymes orchestrate O-glycosylation in a
coordinated manner before and in competition with subsequent
elongation of O-glycans2. In addition, our analysis affords the first
experimental evidence of the molecular mechanism of an
exquisite additional level of control of O-glycosylation.
Moreover, the results from the coarse-grained model suggest
that the basic features, responsible for flexibility and for the
activity profiles, do not depend on the sequence details, so that
the proposed model might apply to other GalNAc-T isoenzymes
and help explain their dynamics and activity profiles.
Together, these findings may guide the rational design of
mechanism-based modulators for this relevant family of enzymes.
The finding of inactive and active conformational states in
GalNAc-Ts together with the motion of the flexible loop and its
association with activity somehow resemble similar features
found for the large family of protein kinases. In general, similar
states and an activation flexible loop, marked by conserved DFG
and APE motifs, are also found in protein kinases and these
structural features have been exploited to discover protein kinase
inhibitors33. We believe that modulators for this particular family
of GalNAc-Ts can be developed using similar approaches that will
also include the targeting of the lectin domains.
Methods
Cloning, site-directed mutagenesis and purification. The expression plasmid
pPICZaAgalnact2 (K75-Q571), previously described16, was used as a template for
introducing the following single amino-acid changes by site-directed mutagenesis
as follows: Trp282Ala and Phe361Ala. Site-directed mutagenesis was carried out
following the QuikChange protocol (Stratagene), using the Phusion Hot Start II
High-Fidelity DNA Polymerase (Thermo Scientific). All plasmids were verified by
sequencing (Sistemas Geno´micos, Valencia, Spain). The mutants were purified
using the purification protocol of the wild-type enzyme described previously16.
Crystallization. In all cases, crystals were grown by hanging drop vapour diffusion
at 18 C. Crystals of the inactive GalNAc-T2 form in complex with the peptide
MUC5AC-Cys13 were obtained by mixing 2 ml of protein solution (a mix formed
by 7mgml 1 GalNAcT-2, 5mM UDP, 5mM MnCl2, 5mM MUC5AC-Cys13
peptide in 25mM Tris (pH 8.0), 0.5mM EDTA and 1mM tris(2-carboxyethyl)
phosphine (TCEP)) with 2 ml of precipitant solution (25% PEG 4,000, 400mM
ammonium sulfate and 100mM sodium citrate pH 6) against 500 ml of precipitant
solution. Crystals of the inactive GalNAc-T2 form in complex with the peptide
MUC5AC-3-13 were obtained by mixing 2 ml of protein solution (a mix formed by
7mgml 1 GalNAcT-2, 5mM UDP, 5mM MnCl2, 6mM MUC5AC-3–13 peptide
in the same buffer described above) with 2 ml of precipitant solution (1.6M
ammonium sulfate and 100mM Tris, pH 9) and equilibrated against 500 ml of
precipitant solution. Crystals of the GalNAc-T2 active form in complex with UDP/
Mnþ 2 and the peptide MUC5AC-13 were obtained in similar conditions as the
inactive forms. The protein solution consisting of 3.5mgml 1 of GalNAcT-2,
5mM UDP, 5mM MnCl2 and 6mM MUC5AC-13 in the same buffer described
above was mixed with the precipitant solution containing 1.6M ammonium sul-
fate, 100mM sodium chloride and 100mM HEPES (pH 7). The crystals were
cryoprotected in saturated lithium sulfate and frozen in a nitrogen gas stream
cooled to 100K.
Structure determination and refinement. All data were processed and scaled
using the XDS package34 and CCP4 software35. Relevant statistics are given in
Table 1. The crystal structures were solved by molecular replacement with Phaser35
and using the PDB entry 4D0T as the template. Initial phases were further
improved by cycles of manual model building in Coot36 and refinement with
REFMAC5 (ref. 37). The final models were validated with PROCHECK38 and
model statistics are given in Table 1. The AUs of the tetragonal crystals contain 1
molecule of GalNAc-T2 (Fig. 1). Coordinates and structure factors have been
deposited in the Worldwide Protein Data Bank (wwPDB, and see Table 1 for the
pdb codes).
Synthesis of peptides and glycopeptides. All peptides were synthesized by
stepwise solid-phase peptide synthesis using the Fmoc strategy on Rink Amide
MBHA resin (0.1mmol). O-a-D-GlcNAc-L-Thr39 or S-a-D-GlcNAc-L-Cys26
building blocks (2 equiv.) were prepared as described in the literature and manually
coupled. The other Fmoc amino acids were coupled in the automated mode in an
Applied Biosystems 433A peptide synthesizer using 10 equiv. and HBTU as a
coupling agent. The O-acetyl groups of the sugar moiety were deprotected in a
mixture of NH2NH2/MeOH (7:3). The derivatives were then released from the
resin, and all acid-sensitive side-chain-protecting groups simultaneously removed
using 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS) and 2.5% H2O,
followed by precipitation with diethyl ether. Finally, all the compounds were
purified by HPLC on a Waters Delta Prep chromatograph (Phenomenex Luna
C18(2) column (10 m, 21.20 250mm2)). Additional details are in Supplementary
Methods.
Tryptophan fluorescence spectroscopy. Fluorescence spectroscopy was used to
determine the dissociation constants of GalNAc-T2 against the peptides MUC5AC,
MUC5AC-13 and MUC5AC-3-13 (ref. 40).
All experiments were carried out in a Cary Eclipse spectrofluorometer (Varian)
at 25 C with GalNAc-T2 at 1 mM, and concentrations of peptides varying from 1
to 500mM in 25mM Tris, 150mM NaCl, pH 7.5. The same experiments were also
performed in the same buffer but containing 400 mM UDP and 1mM MnCl2.
Fluorescence emission spectra were recorded in the 300–400 nm range with an
excitation wavelength of 280 nm, with slit width of 5 nm. The data analysis was
performed in Prism (GraphPad software) considering a model with a single
binding site (see equation (1), where F0 is the intrinsic fluorescence of the enzyme
in the absence of quencher (Q), F1 is the observed fluorescence at a given quencher
concentration, fa is the fractional degree of fluorescence and Kd is the dissociation
constant.
1 F1
F0
¼ f a½Q
Kdþ ½Q ð1Þ
Analysis of the enzymatic reaction by MALDI-TOF-MS. We carried out mass
spectrometry analyses to determine the transfer activity of GalNAc-T2 apo form
and mutants using UDP-GalNAc and the MUC5AC and MUC5AC-13 acceptor
peptides. In vitro glycosylation assays were performed as product development
assays in 50 ml buffer (25mM cacodylic acid sodium, pH 7.4, 10mM MnCl2, 0.25%
Triton X-100), 5mM UDP-GalNAc (Sigma), 0.2mM of acceptor peptides and
0.4 mM of purified GalNAc-T2 wild-type or mutant enzymes at 37 C. For time-
course evaluation, 2 ml of the reaction mixtures were taken at 10min, 20min,
40min, 1 h, 2 h, 4 h, 20 h and 44 h (2mM of UDP-GalNAc and 0.2 mM of enzyme
were added into the above mixture after 20 h reaction to push the reaction for
another 24 h), and analysed by MALDI-TOF-MS. Evaluation of incorporation of
GalNAc residues into peptide substrates was performed by matrix-assisted laser
desorption/ionization–time of flight-mass spectrometry (MALDI-TOF-MS). 2 ml of
reaction mixtures were diluted with 18 ml of 0.1% TFA/H2O, and 1 ml mixed with
1 ml of 10mgml 1 2,5-dihydrobenzoic acid dissolved in ACN/H2O (7:3). Acqui-
sition of MS spectra was performed on MALDI-TOF instrument, Bruker Autoflex
using Bruker FlexControl 3.4 software. Spectra were recorded in the positive ion
mode and the raw spectra were processed by Bruker FlexAnalysis 3.4 software. The
specific activities under linear conditions were inferred from the mass spectrometry
data. One unit of enzyme is defined as the amount of enzyme that transfers 1 mmol
GalNAc in 1min using the standard reaction mixture.
Computational details. MD simulations of the enzyme were performed with the
Amber11 software package. The protein was modelled with the FF99SB force field,
whereas all carbohydrate molecules were modelled with the GLYCAM06 force
field41. A snapshot of the equilibrium MD simulation was taken for the
metadynamics simulations. Additional details are in Supplementary Methods.
AFM imaging. AFM measurements were performed using a MultiMode 8 AFM
system (Bruker). Images were taken using the Tapping Mode with V-shaped silicon
nitride cantilevers with integrated pyramidal 2 nm ultrasharp tips exhibiting a
spring constant and a frequency of 0.03Nm 1 and 15 kHz, respectively (MSNL-D;
Bruker Probes). Additional details are in Supplementary Methods.
SAXS and data analysis. SAXS measurements were performed at the European
Molecular Biology Laboratory on the storage ring PETRA-III (DESY-Hamburg) on
the P12 beamline equipped with a robotic sample changer and a PILATUS-2M.
The analysis of the SAXS data was performed by using the EOM31. Additional
details are in Supplementary Methods.
Coarse-grained model. We used as a template the crystal structure of the Gal-
NAc-T2-UDP-MUC5AC-13 complex to generate our coarse-grained model. The
protein was treated as two interacting rigid domains (the catalytic and the lectin
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domains) joined by a 12-residue semi-flexible linker that is described by a semi-
elastic WLC model32,42,43 (Fig. 5a). We calculated the equilibrium canonical
(Boltzmann) distribution of the end-to-end vector of the linker, as well as that of the
glycopeptide, also considered as a WLC. The probability distribution of the Rg was
derived from that of the end-to-end vector. All calculations were performed with
Wolfram’s Mathematica 9.0. Additional details are in Supplementary Methods.
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